Search

Displaying results 3201 - 3210 of 4539 in total
  1. Drug

    Cyclopentolate

    go.drugbank.com/drugs/DB00979
    Approved

    A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.

    Products: Ak-pentolate
  2. Drug

    Belatacept

    go.drugbank.com/drugs/DB06681
    ApprovedInvestigational

    It was developed by Bristol-Myers-Squibb. Belatacept is only 2 amino acids different from abatacept (Orencia). FDA approved on June 15, 2011.

  3. Drug

    ICG-136

    go.drugbank.com/drugs/DB17343
    Experimental

    ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.

  4. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.

  5. Drug

    Mozafancogene autotemcel

    go.drugbank.com/drugs/DB17723
    Investigational

    RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A

  6. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  7. Drug

    Droxicam

    go.drugbank.com/drugs/DB09215
    ApprovedWithdrawn

    Droxicam is an oxicam non-steroidal anti-inflammatory drug and a prodrug of DB00554. It is used to reduce pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.

  8. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.

  9. Drug

    Miocamycin

    go.drugbank.com/drugs/DB13287
    Approved

    Miocamycin is a macrolide type antimicrobial . This drug may be marketed in Japan for clinical use as it is listed in the Japanese pharmacopeia . It has shown to be effective against several gram-positive and gram-negative microbes and m...

  10. Drug

    Rocakinogene sifuplasmid

    go.drugbank.com/drugs/DB16316
    Investigational

    Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma